Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

AMERICAN HOME PRODUCTS $7 A SHARE ACQUISITION OF VLI CORP., announced Aug. 31, is nearly five times the Today Contraceptive Sponge manufacturer's 1986 sales. VLI reported revenues of approximately $17 mil. at year end, with about 12 mil. shares outstanding. The company has yet to show a profit; in 1986, VLI reported a net loss of $4.9 mil. American Home Products is banking that its marketing and distribution resources can stimulate further growth of the Today brand. Also, the acquisition will give the firm, in the near future, its first entry into the rapidly growing U.S. condom market. Earlier this year, VLI Chairman Robert Elliott estimated the sponge's share of the U.S. OTC female contraceptive market at roughly 30%. American Home has some experience in this market: through its Whitehall division, the company sells Semicid, a vaginal contraceptive insert that uses the same active ingredient, nonoxynol-9. The Today sponge may also have synergies with Wyeth's line of oral contraceptives. The newly formed Wyeth-Ayerst division may choose to detail Today sponge to the physician market as an alternative to the diaphragm for patients starting or coming off oral contraceptives. In addition to the Today Sponge, which accounts for nearly all of the company's revenues, VLI also markets the Today Personal Lubricant, a $475,000 product in 1986. Also, last year VLI entered into an agreement with the British firm Unipath, a subsidiary of Unilever, to market its Clearblue home pregnancy test kit in the U.S. Most recently, VLI has been finalizing an agreement to market a line of condoms under the Today brand, the company said. Unanimously approved by the VLI board, the merger is subject to the reinstatement of a recently expired patent on the contraceptive sponge, approval by VLI shareholders, a waiting period under the Hart-Scott-Rodino Act, and the absence of a material adverse change in the business of VLI. "If all conditions are satisfied, the transaction is anticipated to occur prior to the end of 1987," the companies stated in a joint press release. The conditions also include an option for American Home to purchase up 3 mil. shares of newly issued VLI stock for $7 per share. In November 1986, VLI confirmed that it was engaged in preliminary discussions with another company, rumored to be American Home Products, that was interested in acquiring VLI. A week later, VLI announced that the talks had stalled, due to the concerns over potential product liability costs related to the Today sponge. The negotiations followed the departure of Chairman and founder Bruce Vorhauer, PhD, the previous summer ("The Pink Sheet" Aug. 18, In Brief). Vorhauer had relinquished his CEO responsibilities to Elliott in May 1985.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts